Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM1IZ5D)

Drug Name

Talabostat Drug Info

Synonyms

Talabostat mesylate; Boroproline compounds, DARA BioSciences; Boroproline compounds, Point Therapeutics; PT-100; Val-boro-Pro

Indication

Disease Entry	ICD 11	Status	REF
Constitutional neutropenia	4B00.0	Phase 3	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dipeptidyl peptidase 8 (DPP-8)	TTJGLZF	DPP8_HUMAN	Inhibitor	[2]
Dipeptidyl peptidase 9 (DPP-9)	TTNDUL7	DPP9_HUMAN	Inhibitor	[2]
Prolyl endopeptidase FAP (FAP)	TTGPQ0F	SEPR_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Prolyl endopeptidase FAP (FAP)	DTT	FAP	2.585	3.689	3.018	3.202

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Constitutional neutropenia

ICD Disease Classification

4B00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prolyl endopeptidase FAP (FAP)	DTT	FAP	2.01E-01	0.07	0.84

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007 Nov;6(11):1691-9.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)